These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22902772)
1. Effects of Se-phenyl thiazolidine-4-carboselenoate on mechanical and thermal hyperalgesia in brachial plexus avulsion in mice: mediation by cannabinoid CB1 and CB2 receptors. Del Fabbro L; Borges Filho C; Cattelan Souza L; Savegnago L; Alves D; Henrique Schneider P; de Salles HD; Jesse CR Brain Res; 2012 Sep; 1475():31-6. PubMed ID: 22902772 [TBL] [Abstract][Full Text] [Related]
2. Antinociceptive and anti-hypernociceptive effects of Se-phenyl thiazolidine-4-carboselenoate in mice. Pavin NF; Donato F; Cibin FW; Jesse CR; Schneider PH; de Salles HD; Soares Ldo A; Alves D; Savegnago L Eur J Pharmacol; 2011 Oct; 668(1-2):169-76. PubMed ID: 21756899 [TBL] [Abstract][Full Text] [Related]
3. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. Desroches J; Charron S; Bouchard JF; Beaulieu P Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808 [TBL] [Abstract][Full Text] [Related]
4. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008 [TBL] [Abstract][Full Text] [Related]
5. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913 [TBL] [Abstract][Full Text] [Related]
6. The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Dani M; Guindon J; Lambert C; Beaulieu P Eur J Pharmacol; 2007 Nov; 573(1-3):214-5. PubMed ID: 17651722 [TBL] [Abstract][Full Text] [Related]
7. Development and expression of neuropathic pain in CB1 knockout mice. Castañé A; Célérier E; Martín M; Ledent C; Parmentier M; Maldonado R; Valverde O Neuropharmacology; 2006 Jan; 50(1):111-22. PubMed ID: 16169563 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases. Paszcuk AF; Dutra RC; da Silva KA; Quintão NL; Campos MM; Calixto JB PLoS One; 2011; 6(9):e24034. PubMed ID: 21931637 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146 [TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Eslicarbazepine Acetate in Models of Trigeminal, Neuropathic, and Visceral Pain: The Involvement of 5-HT1B/1D Serotonergic and CB1/CB2 Cannabinoid Receptors. Tomić MA; Pecikoza UB; Micov AM; Stepanović-Petrović RM Anesth Analg; 2015 Dec; 121(6):1632-9. PubMed ID: 26465930 [TBL] [Abstract][Full Text] [Related]
11. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387 [TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Sain NM; Liang A; Kane SA; Urban MO Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975 [TBL] [Abstract][Full Text] [Related]
13. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883 [TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide. Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201 [TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Vincenzi F; Targa M; Corciulo C; Tabrizi MA; Merighi S; Gessi S; Saponaro G; Baraldi PG; Borea PA; Varani K Pain; 2013 Jun; 154(6):864-73. PubMed ID: 23518609 [TBL] [Abstract][Full Text] [Related]
16. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Sterin-Borda L; Del Zar CF; Borda E Biochem Pharmacol; 2005 Jun; 69(12):1705-13. PubMed ID: 15885656 [TBL] [Abstract][Full Text] [Related]
17. CB2 cannabinoid receptor mediation of antinociception. Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625 [TBL] [Abstract][Full Text] [Related]
18. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Fu W; Taylor BK Neurosci Lett; 2015 May; 595():1-6. PubMed ID: 25849525 [TBL] [Abstract][Full Text] [Related]
19. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system. Dutra RC; Simão da Silva KA; Bento AF; Marcon R; Paszcuk AF; Meotti FC; Pianowski LF; Calixto JB Neuropharmacology; 2012 Sep; 63(4):593-605. PubMed ID: 22613837 [TBL] [Abstract][Full Text] [Related]
20. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]